RSS

Q BioMed

Commercial stage biotechnology acceleration development company, Q BioMed, with licensor of Strontium 89 Chloride, BioNucleonics, have announced the submission of a supplemental regulatory filing for a new manufacturing facility. Read more

News

Commercial stage biotechnology acceleration development company, Q BioMed, has extended its option agreement with Washington University in St Louis for a novel companion biomarker for monitoring glaucoma and initiation of a clinical study. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Commercial stage biotechnology acceleration development company, Q BioMed, and Bio-Nucleonics, licensor of Strontium-89 Chloride, have filed for regulatory approval of a new manufacturing facility by the US Food and Drug Administration (FDA). Read more

Technology

Q BioMed, a biomedical acceleration and development company, has signed an exclusive option agreement with Washington University in St Louis for a novel companion biomarker for monitoring glaucoma. Read more

News

Biotechnology acceleration company, Q BioMed, has announced its successful development of a new and proprietary analogue of QBM-001 in partnership with Sphaera Pharma for paediatric nonverbal disorder. Read more

News